MOLECULAR PARTNERS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.26 CHF | -4.54% |
|
-3.41% | -5.23% |
| Mar. 15 | Transcript : Molecular Partners AG, 2023 Earnings Call, Mar 15, 2024 | |
| Mar. 15 | Molecular Partners Swings to Loss in FY23; Revenue Down | MT |
| Sales 2024 * | 13.86M 0 | Sales 2025 * | 18.66M 0 | Capitalization | 107M 0 |
|---|---|---|---|---|---|
| Net income 2024 * | -59M - | Net income 2025 * | -61M - | EV / Sales 2024 * | 7.73 x |
| Net cash position 2024 * | - - | Net cash position 2025 * | - - | EV / Sales 2025 * | 5.74 x |
| P/E ratio 2024 * |
-1.92
x | P/E ratio 2025 * |
-1.76
x | Employees | 168 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.11% |
More Fundamentals
* Assessed data
More news
Latest transcript on Molecular Partners AG
More recommendations
More press releases
| 1 day | -4.54% | ||
| 1 week | -3.41% | ||
| Current month | -11.29% | ||
| 1 month | -6.86% | ||
| 3 months | -20.49% | ||
| 6 months | -1.36% | ||
| Current year | -5.23% |
1 week
3.25
3.51
1 month
3.253.84
Current year
3.204.57
1 year
3.046.30
3 years
3.0428.90
5 years
3.0428.90
10 years
3.0438.75
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 52 | 04-11-22 | |
Patrick Amstutz
FOU | Founder | 49 | 04-11-22 |
Michael Pitzner
CMP | Compliance Officer | - | 22-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
William Burns
CHM | Chairman | 76 | 17-10-30 |
Steven Holtzman
BRD | Director/Board Member | 70 | 14-09-18 |
Vito Palombella
BRD | Director/Board Member | 61 | 20-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 3.26 | -4.54% | 3,428 |
| 24-04-23 | 3.415 | +3.48% | 3,527 |
| 24-04-22 | 3.3 | -2.08% | 355 |
| 24-04-19 | 3.37 | +0.60% | 24,802 |
| 24-04-18 | 3.35 | -0.74% | 3,637 |
Delayed Quote Swiss Exchange, April 24, 2024 at 11:31 am EDT
More quotes
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.26
CHF
Average target price
9.35
CHF
Spread / Average Target
+186.81%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -5.23% | 117M | |
| -1.51% | 104B | |
| +3.22% | 97.42B | |
| +1.86% | 22.2B | |
| -16.53% | 21.23B | |
| -8.49% | 18.33B | |
| -42.33% | 16.35B | |
| -20.09% | 15.06B | |
| +5.47% | 13.98B | |
| +28.85% | 11.66B |
- Stock Market
- Equities
- MOLN Stock
